Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP982561priorityCriticalpatent/ECSP982561A/en
Publication of ECSP982561ApublicationCriticalpatent/ECSP982561A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
33-epicloro-33 desoxiascomicina de la fórmula I: (gráfico), y diferentes formas tautoméricas o solvatadas de la misma, en forma cristalina, tal como la forma A y la forma B. Su preparación involucra convertir apropiadamente el compuesto amorfo de la fórmula 1, o el compuesto de la fórmula I en una forma diferente de la forma A, o el compuesto de la fórmula I en una forma diferente de la forma B, respectivamente, a partir de una solución del mismo, bajo condiciones que induzcan cristalización, o bajo condiciones que induzcan cristalización prefencial de la forma A ó B respectivamente, estos crsitales se indican particularmente para utilizarse en la preparción de formas galénicas locales del compuesto para uso farmacéutico, por ejemplo cremas, emulsiones y uguentos.33-epichloro-33 deoxiascomycin of formula I: (graph), and different tautomeric or solvated forms thereof, in crystalline form, such as form A and form B. Their preparation involves appropriately converting the amorphous compound of the formula 1, or the compound of formula I in a different form than form A, or the compound of formula I in a different form of form B, respectively, from a solution thereof, under conditions that induce crystallization, or under conditions that induce pre-crystallization of form A or B respectively, these crystals are particularly indicated for use in the preparation of local galenic forms of the compound for pharmaceutical use, for example creams, emulsions and ointments.
MACROLIDAS CRISTALINAS, A PROCESS FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH COMPOUNDS FOR THE PREPARATION OF A MEDICINAL PRODUCT
A METHOD FOR CRYSTALLIZING 1- [2- (2-NAFTIL) ETIL] -4- (3-TRIFLUOROMETIL-FENIL) -1,2,3,6-TETRAHIDROPIRIDINA, A MIXTURE OF FORMS I AND OF FORM III OF SAID 1- [2- (2-NAFTIL) ETIL] -4- (3-TRIFLUOROMETIL-FENIL) -1,2,3,6-TETRAHYDROPYRIDINE; AND A PHARMACEUTICAL COMPOSITION FOR
Compound derived from gamma-lactone of the steroid of 15,16-methylene-17-hydroxy-19-nor-21-carboxylic acid, intrauterine device containing it and its use for oral contraception and for pre, peri and postmenopausal disorders.